The slides in question compared the safety profile of IFN-lambda monotherapy side by side with the safety profile of IFN-alpha plus ribavirin (from separate trials).
I made a similar comment (albeit without the term 'disingenuous') - that they seem to have had a problem similar to mine in finding comparible monotherapy data on platelets and neutrophils. That said, they probably should have caveated it somehow.
PS I have literally no idea how much of the SAEs are caused by IFN-A, how much by ribavirin and how much by synergy. I haven't finished looking yet - but ... .
How is it disingenuous? I think everyone knows that comparing lambda data to historical alpha data doesn't mean much. However, such a dramatic difference in tolerability is still encouraging and is in line with MOA of lambda. If you expect the safety profile to be a lot worse when combined with ribavirin, will the efficacy also be far more superior compared to the alpha combo based on the CC slide?
Market Data 
Markets 
AI
